Clinical Trial Detail

NCT ID NCT03021460
Title Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Mayo Clinic
Indications

melanoma

Therapies

Ibrutinib + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.